On Wednesday, Shares of The Coca-Cola Co (NYSE:KO), subtract -1.42% and closed at $42.27 in the last trading session. The last trading range of the stock ranges between $41.70 and $42.32. The company’s Market capitalization is $184.11 Billion with the total Outstanding Shares of 4.31 billion. New Colombia Resources, Inc.(OTC: NEWC) (the “Company”), a U.S. listed Colombian resource company with premium metallurgical coal and medical marijuana assets, is happy to declare they will be featured in an forthcoming documentary on the country’s changing beliefs of the cultivation of medicinal marijuana and coca. Sannabis, the company’s medical marijuana joint venture, with the assist of New Colombia President John Campo, will host a film crew at their Cauca region’s collective farms. These areas have the cooperation from its local population, and government to medically produce products that have known positive medicinal uses.
New Colombia Resources believes this documentary will enhance product sales in Colombia and abroad.
Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $40.75 and reached to max level of $47.13. The EPS of company is strolling at 1.65.
Shares of AbbVie Inc (NYSE:ABBV), jumped 6.51% and closed at $62.64 in the last trading session. The last trading range of the stock ranges between $60.41 and $64.69. The company’s Market capitalization is $101.62 Billion with the total Outstanding Shares of 1.63 billion. AbbVie (ABBV), a global biopharmaceutical company, recently declared that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to veliparib, an oral poly (adenosine diphosphate [ADP]-ribose) polymerase (PARP) inhibitor, being investigated in combination with chemotherapies, such as carboplatin and paclitaxel, or radiation for the treatment of advanced squamous non-small cell lung cancer (NSCLC).
PARP is a naturally-occurring enzyme in the body that repairs damage to DNA in cells. While this repair is a useful process to maintain the integrity of healthy cells, the same process may also assist repair DNA in cancer cells, causing them to survive.3 Researchers are investigating whether veliparib, a PARP inhibitor, in combination with DNA damaging therapies, such as chemotherapy or radiation, may lessen the repair of DNA damage in cancer cells, eventually causing some cells to die.3
NSCLC is the most common type of lung cancer in the U.S., accounting for about 80 to 85 percent of diagnosed cases.2 Survival in people with lung cancer can vary depending on the stage, or extent, of the cancer when it is diagnosed.2 Squamous cell carcinoma accounts for about 25 to 30 percent of NSCLC cases.2 It is usually found in the middle airways of the lungs and is often linked to a history of smoking.2
Technical Analysis: During the 52-week trading session the minimum price at which share price traded, registered at $50.71 and reached to max level of $68.12. The EPS of company is strolling at 3.72.